CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 72 enrolled
Drug / intervention
Prone to Supine MRIother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03573804
NCT03573804N/ACompleted
CompareCT.gov

The Prone to Supine Breast MRI Trial

Dartmouth-Hitchcock Medical Center·interventional·Posted Jun 29, 2018·Updated Aug 30, 2021

In Brief

A clinical study evaluating Prone to Supine MRI for Breast Cancer. Completed, enrolled 72 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether a supine MRI obtained immediately after a standard diagnostic prone MRI exam, without a second injection of gadolinium (Gd) contrast material, would be of sufficient quality to allow the Radiologist to define the tumor edges ("segment" the tumor) so that a 3-D image of the tumor can be generated to form a BCL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJun 29, 2018
Enrollment StartJul 12, 2018
Primary CompletionJul 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.0 years ago

Interventions

Prone to Supine MRIother

The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.